Sequenom jumps 7% to 52-week high on lifted price target
Sequenom Inc. (Nasdaq:SQNM) is up more than 7% to a 52-week high in today’s trading after Lazard Capital raised its price target to $26 from $20. The genetics and molecular diagnostic company, which is based in San Diego, expects to market its Down’s syndrome test directly in the United States without a partner. The test may produce more accurate results than hormone tests.
During the past 52-weeks, shares of Sequenom have ranged from $4.25 to today’s high of $19.70. In today’s trading, Sequenom is at $19.59 at 11:48 a.m. ET on below-average volume, up $1.39 from Friday’s close.
For detailed price information and recent news stories about Sequenom Inc., click SQNM.
